LU90911I2 - Antig-ne recombinant comprenant les s-quences pre-S1 et S du virus de l'h-patite B ingr-dient actif de hepacare - Google Patents

Antig-ne recombinant comprenant les s-quences pre-S1 et S du virus de l'h-patite B ingr-dient actif de hepacare

Info

Publication number: LU90911I2
Authority: LU; Luxembourg
Prior art keywords: hepacare; hepatitis; sequences; active ingredient; recombinant antigen
Prior art date: 1987-06-22

Application number

LU90911C

Other languages

English (en)

Original Assignee

Medeva Holdings Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-06-22

Filing date

2002-04-19

Publication date

2002-06-19

2002-04-19 Application filed by Medeva Holdings Bv filed Critical Medeva Holdings Bv

2002-06-19 Publication of LU90911I2 publication Critical patent/LU90911I2/fr

Links

241000700721 Hepatitis B virus Species 0.000 title 1
239000004480 active ingredient Substances 0.000 title 1
239000000427 antigen Substances 0.000 title 1
102000036639 antigens Human genes 0.000 title 1
108091007433 antigens Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10123—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Virology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Physics & Mathematics (AREA)
Toxicology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

LU90911C 1987-06-22 2002-04-19 Antig-ne recombinant comprenant les s-quences pre-S1 et S du virus de l'h-patite B ingr-dient actif de hepacare LU90911I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP87108915		1987-06-22
EP87108914		1987-06-22
EP88109946A EP0304578B1 (fr)	1987-06-22	1988-06-22	Peptide contenant l'antigène de surface de l'hépatite B

Publications (1)

Publication Number	Publication Date
LU90911I2 true LU90911I2 (fr)	2002-06-19

Family

ID=27230073

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU90911C LU90911I2 (fr)	1987-06-22	2002-04-19	Antig-ne recombinant comprenant les s-quences pre-S1 et S du virus de l'h-patite B ingr-dient actif de hepacare

Country Status (3)

Country	Link
EP (2)	EP1088830A3 (fr)
LU (1)	LU90911I2 (fr)
NL (1)	NL300090I2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0300213A1 (fr) *	1987-06-22	1989-01-25	Hexal-Pharma Gentechnik GmbH & Co. KG	Particules immunogènes peptidiques virales d'hépatite A
PL168787B1 (pl) *	1989-08-03	1996-04-30	Smithkline Beecham Biolog	Sposób wytwarzania czastki kompozytowej PL
EP0491077A1 (fr) *	1990-12-19	1992-06-24	Medeva Holdings B.V.	Composition utilisée comme agent thérapeutique contre des maladies hépatiques chroniques
JP2904993B2 (ja) *	1991-10-09	1999-06-14	ロート製薬株式会社	オキシトシン受容体およびこれをコードするｄｎａ
SG48365A1 (en)	1992-05-23	1998-04-17	Smithkline Beecham Biolog	Combined vaccines comprising hepatitis b surface antigen and other antigens
CA2138997C (fr)	1992-06-25	2003-06-03	Jean-Paul Prieels	Composition vaccinale qui contient des adjuvants
EP0637631A3 (fr) *	1993-07-30	1996-08-21	Immuno Ag	Expression à très bon rendement d'un polypeptide contenant une région préS1 modifiée de l'antigène majeur du virus hépatitis B.
WO1997008309A2 (fr) *	1995-08-29	1997-03-06	Immusol, Inc.	Therapie utilisant de ribozymes contre les infections a virus de l'hepatite b
GB9623233D0 (en)	1996-11-07	1997-01-08	Smithkline Beecham Biolog	Vaccine composition
KR100629028B1 (ko)	1998-10-16	2006-09-26	글락소스미스클라인 바이오로지칼즈 에스.에이.	애쥬번트 시스템 및 백신
UA79735C2 (uk) *	2000-08-10	2007-07-25	Глаксосмітклайн Байолоджікалз С.А.	Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
GB0109297D0 (en)	2001-04-12	2001-05-30	Glaxosmithkline Biolog Sa	Vaccine
EP1281761A1 (fr) *	2001-07-27	2003-02-05	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Polypeptides synthetiques derivées du proteine pre-S1 de Hepatitis B virus et utilisations associées
ATE500267T1 (de)	2003-07-21	2011-03-15	Transgene Sa	Multifunktionelle cytokine
TWI457133B (zh)	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
JP5814507B2 (ja)	2006-09-07	2015-11-17	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
PL2068918T5 (pl)	2006-09-26	2024-12-02	Access To Advanced Health Institute	Kompozycja szczepionki zawierająca syntetyczny adiuwant
EP2433648A3 (fr)	2006-10-12	2012-04-04	GlaxoSmithKline Biologicals S.A.	Vaccin comprenant une émulsion adjuvante huile en l'eau
EA015817B1 (ru)	2006-10-12	2011-12-30	Глаксосмитклайн Байолоджикалс С.А.	Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
PE20090146A1 (es)	2007-04-20	2009-03-23	Glaxosmithkline Biolog Sa	Composicion inmunogenica contra el virus influenza
JP2010525035A (ja)	2007-05-02	2010-07-22	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
WO2009143524A2 (fr)	2008-05-23	2009-11-26	The Regents Of The University Of Michigan	Vaccins à nanoémulsion
CA2764374C (fr)	2009-06-05	2019-11-19	Infectious Disease Research Institute	Adjuvants lipidiques synthetiques a base de glucopyranosyle
EA201690310A1 (ru)	2010-04-13	2016-12-30	Селлдекс Терапьютикс Инк.	Антитела, связывающие cd27 человека, и их применение
GB201105981D0 (en)	2011-04-08	2011-05-18	Glaxosmithkline Biolog Sa	Novel process
EA027236B1 (ru)	2011-04-08	2017-07-31	Иммьюн Дизайн Корп.	Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
ES2729967T3 (es)	2012-02-07	2019-11-07	Infectious Disease Res Inst	Formulaciones de adyuvante mejoradas que comprenden agonistas de TLR4 y métodos para usar las mismas
HRP20181102T1 (hr)	2012-05-16	2018-09-07	Immune Design Corp	Cjepiva za hsv-2
EP3587455A1 (fr)	2012-10-23	2020-01-01	Emory University	Conjugués de gm-csf et d'il-4, compositions et procédés associés
ES2728243T3 (es)	2012-11-12	2019-10-23	Univ Heidelberg Ruprecht Karls	Lipopéptidos para su uso en el tratamiento de enfermedades hepáticas y enfermedades cardiovasculares
MX370573B (es)	2013-04-18	2019-12-17	Immune Design Corp	Monoterapia con glucopiranosil lipido a para usarse en el tratamiento del cancer.
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
IL310015B2 (en)	2013-12-31	2026-02-01	Access To Advanced Health Inst	Single vial formulation
WO2016145085A2 (fr)	2015-03-09	2016-09-15	Celldex Therapeutics, Inc.	Agonistes cd27
US12297266B2 (en)	2016-04-18	2025-05-13	Celldex Therapeutics, Inc.	Agonistic antibodies that bind human CD40 and uses thereof
MX2018014086A (es)	2016-05-16	2019-09-18	Infectious Disease Res Inst	Formulacion que contiene agonista tlr y metodos de uso.
WO2017200957A1 (fr)	2016-05-16	2017-11-23	Infectious Disease Research Institute	Liposomes pégylés et procédés d'utilisation
KR20250008135A (ko)	2016-06-01	2025-01-14	액세스 투 어드밴스드 헬스 인스티튜트	사이징제를 함유하는 나노명반 입자
MX2019015076A (es)	2017-06-15	2020-08-03	Infectious Disease Res Inst	Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos.
WO2019051149A1 (fr)	2017-09-08	2019-03-14	Infectious Disease Research Institute	Formulations liposomales comprenant de la saponine et procédés d'utilisation
CA3097369A1 (fr)	2018-04-17	2019-10-24	Celldex Therapeutics, Inc.	Anticorps anti-cd27 et anti-pd-l1 et constructions bispecifiques
WO2020123444A1 (fr)	2018-12-11	2020-06-18	Celldex Therapeutics, Inc.	Procédés d'utilisation d'anticorps cd27 en tant que traitement de conditionnement pour une thérapie cellulaire adoptive
CA3141577A1 (fr)	2019-05-25	2020-12-03	Infectious Disease Research Institute	Composition et procede de sechage par atomisation d'une emulsion de vaccin et d'adjuvant
WO2022051022A1 (fr)	2020-09-04	2022-03-10	Infectious Disease Research Institute	Arn co-lyophilisé et support lipidique nanostructuré
CA3214853A1 (fr)	2021-04-09	2022-10-13	Celidex Therapeutics, Inc.	Anticorps contre l'anticorps ilt4, anti-ilt4/pd-l1 bispecifique et ses utilisations
WO2023077521A1 (fr)	2021-11-08	2023-05-11	Celldex Therapeutics, Inc	Constructions bispécifiques anti-ilt4 et anti-pd-1
CA3266697A1 (fr)	2022-09-09	2024-03-14	Access To Advanced Health Institute	Composition de vaccin immunogène incorporant une saponine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2560890B1 (fr) *	1984-03-07	1987-10-16	Grp Genie Genetique	Composition utile pour la fabrication de vaccins contenant des particules portant l'antigene de surface du virus de l'hepatite b et le recepteur de l'albumine serique humaine polymerisee, cellules animales capables de produire de telles particules et procede pour leur obtention
EP0180012A1 (fr) *	1984-10-27	1986-05-07	Wolfram H. Prof. Dr. Gerlich	Séquence de polypeptide immunogène du virus de l'hépatite B
US4683136A (en) *	1985-03-06	1987-07-28	Scripps Clinic And Research Foundation	Proteinaceous antigens with conformation-independent and conformation-dependent determinants
FI861417A0 (fi) *	1985-04-15	1986-04-01	Endotronics Inc	Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4816564A (en) *	1986-01-31	1989-03-28	Merck & Co., Inc.	Method for producing hepatitis B virus proteins in yeast
CA1310602C (fr) *	1986-06-03	1992-11-24	Hajime Horii	Promoteur de la levure et procede pour la preparation de proteines heterologues
JPH01500515A (ja) *	1986-06-20	1989-02-23	スクリップス　クリニック　アンド　リサーチ　ファウンデーション	Ｂ型肝炎ウィルス表面抗原のプレｓ領域のｔ及びｂ細胞エピトープ

1988
- 1988-06-22 EP EP00121167A patent/EP1088830A3/fr not_active Withdrawn
- 1988-06-22 EP EP88109946A patent/EP0304578B1/fr not_active Expired - Lifetime
2002
- 2002-04-19 LU LU90911C patent/LU90911I2/fr unknown
- 2002-04-19 NL NL300090C patent/NL300090I2/nl unknown

Also Published As

Publication number	Publication date
EP0304578A1 (fr)	1989-03-01
EP1088830A2 (fr)	2001-04-04
NL300090I2 (nl)	2002-12-02
EP1088830A3 (fr)	2004-04-07
EP0304578B1 (fr)	2001-10-24
NL300090I1 (nl)	2002-07-01

Publication	Publication Date	Title
LU90911I2 (fr)	2002-06-19	Antig-ne recombinant comprenant les s-quences pre-S1 et S du virus de l'h-patite B ingr-dient actif de hepacare
OA08801A (fr)	1989-03-31	Antigènes de surface du virus de l'hépatite B et antigènes hybrides les contenant.
BR9206131A (pt)	1995-05-02	Hepatite C: diagnóstico e vacinas
ITMI931522A0 (it)	1993-07-12	Composizione farmaceutiche per il trattamento dell'infezione da virus dell'epatite b (hbv)
FR2647808B1 (fr)	1995-03-03	Poxvirus recombinant et vaccin contre le virus de l'herpes contenant ce poxvirus
LV10726A (lv)	1995-06-20	Hepatita C virusa diagnostikas lidzekli un vakcinas
EP0550528A4 (en)	1994-05-18	Active site of interleukin-8: polypeptide analogs and antibodies
IT1229484B (it)	1991-09-03	Virus ricombinante delle malattie esantematiche dei vertebrati.
CY2007030I1 (el)	2012-01-25	Εμβολιο εναντια στον ανθρωπινο ϊο θηλωματος (τυπος 18)
GB2212511B (en)	1992-01-22	Hepatitis c virus
GB2213823B (en)	1991-04-03	Synthetic peptides for use in the diagnosis and prevention of influenza virus infection
KR890002547A (ko)	1989-04-10	Hiv 감염의 치료 및 진단용 모노클로날항체 및 펩티드
ZA831854B (en)	1984-01-25	Small peptides with the specificity of foot and mouth disease viral antigens
FI925261A7 (fi)	1992-11-19	Virushepatiitin diagnoosi ja hoito
PT85137A (en)	1987-07-01	T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen
FR2619012B1 (fr)	1989-12-22	Vaccins dont l'epitope caracteristique est incorpore dans une proteine de picornavirus, notamment de poliovirus
FR2689398B1 (fr)	1994-11-18	Compositions destinées au traitement de l'infection et des maladies provoquées par le virus de l'hépatite B (HBV).
NO892269L (no)	1989-12-04	Ikke-hyperglykosylerte hepatitt b-virus-proteiner samt ekspresjons-"kassetter" og fremgangsmaate for fremstilling avproteinene.
FI883723A7 (fi)	1988-08-10	Ihmisen monoklonaaliset vasta-aineet ja niitä vaikuttavana aineosana s isältävät terapeuttiset aineet infektiotauteja vastaan
KR890701743A (ko)	1989-12-21	B형 간염 표면 항원 백신
IT8221787A0 (it)	1982-06-09	Procedimento per la preparazione di antigene superficiale puro dell'epatite b da plasma umano.
FR2604434B1 (fr)	1989-05-19	Derives d'amino-2 ethanethiol, leur preparation et leur application en therapeutique
BR9106503A (pt)	1993-06-22	Diagnostico e tratamento de hepatite viral
FR2602681B1 (fr)	1990-05-18	Procede de preparation d'un vaccin recombinant contre l'hepatite b
JPS6471488A (en)	1989-03-16	Preparation of human immunodeficient virus type i antigen, and its use as diagnostic and curing agents